The therapies to target EGFR signaling pathways have limited clinical benefits in GBM treatment [60,61,62], but EGFR has been demonstrated as a good surface target, and the anti-EGFR mAb or peptide can direct the targeted delivery of therapies to GBM [45,63,64,65,66]. This evidence concerns the gene EGFR and glioblastoma.